MarginsXMarginsX
Home › Markets › Health Care › CMPX

Compass Therapeutics Inc. (CMPX)

CMPX trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.6615
-14.51% on the day
Market cap
$119.1M
Micro cap
Revenue · 2025
$0
-100.0% on 2024
Net income · 2025
-$66.5M

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1738021/000117184326001337/0001171843-26-001337-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerCMPX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001738021
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2025

LineValue
Revenue$0
Net income-$66.5M
Operating income-$72.8M
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growth-100.0%
Cash$30.6M
Total assets$219.6M
P/E (computed)Net income was not positive
P/S (computed)Needs market cap and revenue

Warning signs

Cash runway
8.1 months
$41.5M cash at September 30, 2026
Share count, 1 year
+1.3%
2025-10-30 to 2026-11-05 · +41.3% over 3 years
Going-concern doubt
No
10-Q filed November 9, 2026
Insider net buying, 12 months
$78K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-09
Cash and burn$41.5M cash; operating cash flow -$15.4M a quarter.Report 2026-09-30
Shares outstanding180,087,915 (2026-11-05); 177,862,102 a year earlier; 127,486,326 three years earlier.Cover page 2026-11-05
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2025-12-30
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorCohnReznick LLP, Melville, New York, United StatesPCAOB Form AP 2026-03-17
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $78K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$27.2M-$16.3M$41.5MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q2 2026
2026-06-30
Not filed-$25.2M-$14.7M$35.5MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q1 2026
2026-03-31
Not filed-$18.3M-$17.3M$55.2MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q4 2025
2025-12-31
$0-$15.7M-$13.3M$30.6MNo debt tags$010-K 2026-03-05
Q3 2025
2025-09-30
$0-$14.3M-$10.8M$46.2MNo debt tagsNeeds four quarters10-Q 2025-11-05
Q2 2025
2025-06-30
$0-$19.9M-$11.8M$22.9MNo debt tagsNeeds four quarters10-Q 2025-08-11
Q1 2025
2025-03-31
Not filed-$16.6M-$13.2M$41.0MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q4 2024
2024-12-31
$0-$15.0M-$9.2M$43.5MNo debt tags$850K10-K 2026-03-05

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32025-12-30
Latest annual report
FORM 10-K
10-K2026-03-05
Latest quarterly / interim
FORM 10-Q
10-Q2026-11-09
Latest current report
FORM 8-K
8-K2026-11-09
Latest proxyDEFA14A2026-04-29

Source: SEC EDGAR submissions feed, 362 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+2.0%
1 month-9.7%
3 months-65.8%
Year to date-85.6%
1 year-83.8%
From 52-week high-88.4%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
LENZLENZ Therapeutics Inc.$3.82-7.51%$120.0M
CRDLCardiol Therapeutics Inc. Class A Common Shares$0.9798-2.02%$125.1M
ENGNenGene Therapeutics Inc.$1.89-21.58%$126.7M
ARMPArmata Pharmaceuticals Inc.$2.99-22.74%$111.2M
ZURAZura Bio Limited$1.08-12.90%$104.0M
FATEFate Therapeutics Inc.$1.14-10.94%$138.6M
VYGRVoyager Therapeutics Inc.$1.63-5.78%$101.4M
MOLNMolecular Partners AG$2.70-8.21%$101.2M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier